MSD reports positive topline data from Phase IIb/III RSV trial in infants
Clesrovimab was found to reduce the instances of RSV-linked, medically attended lower respiratory infection up to day 150.
24 July 2024
24 July 2024
Clesrovimab was found to reduce the instances of RSV-linked, medically attended lower respiratory infection up to day 150.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.